
- Medicine - Atrial Fibrillation

Types	
Paroxysmal spor	ntaneous termination within 7 days
Persistent requ	uires cardioversion to restore sinus rhythm
Permanent sinu	s rhythm cannot be restored
Treatment	
Freq. control	goal <110/min
	T Bisoprolol 2.5-5 mg
	T Digoxin 0.13-0.25 mg if heart failure
Rhythm control	if symtomatic
Paroxysmal	T flekainid (Tambocor) 50-100 mg x2
Persistent	Electrical cardioversion
	AF <48 h \rightarrow no anticoagulants needed AF >48 h \rightarrow anticoagulants > 3 weeks
	before procedure (alternative: TEE)
Anticoagulants	If CHA ₂ DS ₂ -VASc > 2
	1. NOAK, ex. dabigatran (Pradaxa)
	2. Warfarin (Waran)
	3. Long-term treatment with LMH

- Medicine - Spirometry



- Medicine -

	Mortality % (untreated) after 1 re	esp. 5	years
NYHA	Symptoms	1 y	5 y
ı	Impaired heart function without symptoms	5	20
II	Shortness of breath and fatigue only during strenuous exercise	10	30
III a	Shortness of breath and fatigue during light to medium exercise	25	60
III b	III a, and cannot walk >200m	Sam III	e as a
IV	Shortness of breath and fatigue at rest. Often confined to bed.	50	80

New York Heart Association (NYHA) Functional Classification

Diagnostics modalities for heart failure (HF)

Heart ultrasound (confirms the diagnosis)

ECG (normal ECG speaks strongly against HF)

Plain film X-ray (heart/lung, to exclude other conditions)

NT-proBNP (if low + ok ECG, rules out HF w. high certainty)

Lab tests (Hb, Na, K, Crea., PK, B-glucose, TSH, CRP, iron)

- Medicine - CHA2DS2VAS

С	Cardiac - Heart failure	1
Н	Hypertension	1
A	Age ≥ 75 years	2
D	Diabetes	1
S	Stroke / TIA / Embolism	2
V	Vascular Atherosclerotic disease	1
A	Age 65-74	1
S	Sex - Female*	1

*No indication for antithrombotic treatment if only risk factor

AF and score ≥2 → Antithrombotic treatment *IF* low-medium risk of bleeding (HAS-BLED <3)

See local guidelines for specific antithrombotic drugs

Example of initial Warfarin treatment, 2.5mgx1 p.o.

Day 1: 2-4 | Day 2: 2-3 | Day 3: 1-4 (dep. on INR)

- Medicine - Heart Failure Treatment

NYHA Treatment when EF <45%

ACE inhibitor*

I If symptomatic oedema
Diuretic

Beta-blocker (slow increase in dose)

If EF <35%

II Aldosterone receptor antagonist

If EF <35% and QRS >120 ms

Assess need for CRT and/or ICD

III + IV Advanced treatment/palliative care.

*If not tolerated → Angiotensin II receptor antagonist, EF = Ejection Fraction

Drug class	Example	Start (mg)	Target (mg)
ACE-Inhibitor	Enalapril	2.5 x 2	10-20 x 2
Diuretic	Furix	20 - 40	40 - 240
Beta-blocker	Bisoprolol	1.25 x 1	10 x 1
Aldosterone antagonist	Spironolakton	25 x 1	25-50 x 1
Angiotensin II antagonist	Candesartan	4-8 x 1	32 x 1

Acute heart failure (left ventricle)

Heart position

Oxygen (target SaO2 >90%) or CPAP if severe lung oedema

Furosemid (10 mg/ml 2-4 ml i.v.)

Nitroglycerin i.v. (0.25-0.5 mg) or

spray (0.4 mg) sublingually if systolic BP >100

- Medicine - HAS-BLED

Hypertension >160 mmHg	1
	Hypertension >160 mmHg

	Α	Abnormal	liver o	r kidnev*	1-2
--	---	----------	---------	-----------	-----

_	- 4 .	
S	Stroke	1

R	Bleeding	1
	Previous tendency or anaemia	•

Labile INR

L High / Unstable INR or <60% time in therapeutic range

E Elderly (>65 years) 1

Drugs D E.g. ASA. NSAID or 1.

D E.g. ASA, NSAID or high alcohol consumption

* Kidney: Creatinine >200, dialysis, or transplant Liver: Chronic liver disease, Bilirubin 2x ref, or ALAT/ASAT/ALP 3x ref.

High risk of bleeding if ≥3 points

- Medicine -